Leading Imaging CRO Delivers High-Quality Data with Rapid Turnaround Times
Boston, MA, February 28, 2017 -- WorldCare Clinical (WCC), a leading provider of imaging services for clinical trials in hematological and oncological diseases, today announced how its technology system and clinical reviewer network enable high-quality reviews and rapid turnaround times in multi-center Phase
III beta thalassemia clinical trials.
Beta thalassemia is an inherited blood disorder that reduces
the production of hemoglobin. Hemoglobin
is the iron-containing protein in red blood cells that transports oxygen
throughout the body.
In a particular Phase III program for beta thalassemia, WCC
performs rapid (48-hour turnaround time), automated site notification of three
distinct independent assessments of pediatric MRIs. These assessments occur concurrently by three
separate reviewer groups.
The first assessment is a quantification of liver/spleen
volumes. This assessment is performed by
radiologists from the Harvard Hospital System.
The second assessment is of incidental findings using board-certified
radiologists from ProScan Imaging, WCC's parent and teleradiology service with
more than 30 board-certified, subspecialty-trained radiologists on staff. The third assessment is of liver and heart
iron concentration through a collaboration with the University of Southern
California Professor of Cardiology John Wood MD, PhD, who pioneered
the non-invasive MRI method of assessing iron concentration.
This rapidity of assessment and notification is made
possible by WorldCare's proprietary Web-based technology platform. The system permits reviewers from any
computer with an Internet connection to review images through a secure
portal. In addition, the system easily
integrates with best-in-breed analysis software to enable the most precise
measurements. This flexibility of
integration is particularly helpful in clinical trials which require advanced
"WorldCare offers rapid communication of independent central
review results seamlessly through the combination of expert clinical
assessments with our advanced, Web-based technology platform," stated Aaron
Timm, CEO of WorldCare Clinical. "We've
found that our approach has been well received by sponsors seeking high quality
results with transparent and efficient reporting."
About WorldCare Clinical
WorldCare Clinical is a global imaging CRO that employs scientific expertise, innovative technology, and operational excellence to maximize the precision and accuracy of a blinded independent central review of Phase I – IV clinical trial data. The company has worked with thousands of sites in more than 60 countries. WCC's robust technology platform processes over 250 million images annually (CT, MRI, X-Ray, Echo, US, PET). Originally founded in 1992 by the Massachusetts General Hospital (MGH) Department of Radiology, WorldCare continues to maintain a strategic relationship with the Harvard Hospital System as well as other leading academic institutions.
For more information on WCC's services, please visit our website at www.wcclinical.com or contact: